Effect of thymalfasin (Thymosin-α-1) on reversing lymphocytopenia among patients with COVID-19

ABSTRACT:

Introduction

Thymosin-α-1 (Tα1) elevates lymphocyte counts among patients with COVID-19, but its effect on reversing lymphocytopenia is unknown.

Methods

24 patients treated with Tα1 and 100 patients in the control arm were included in this analysis. The incidence rate of reversing lymphocytopenia, overall and stratified by baseline oxygen support, above the threshold for classification of lymphocytopenia (i.e., Total Lymphocyte Count (TLC) < 1.5 × 109/L) and severe lymphocytopenia (i.e., TLC < 1.0 × 109/L) within 3, 5, and 7 days of treatment initiation was calculated, along with incidence rate ratios (IRRs) and 95 % confidence intervals (CIs).

Results

Compared with the standard of care, the rate of reversing lymphocytopenia (IRR: 2.38, 95 % CI: 0.92 – 5.81) and

SUBMITTER: Benitez G 

PROVIDER: S-EPMC9902288 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature